Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular relapse can be detected in blood in a sensitive and timely fashion in B-lineage acute lymphoblastic leukemia.

Leukemia·2001
Same author

Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia.

Leukemia·2001
Same author

Early resistance to therapy during induction in childhood acute lymphoblastic leukemia.

Cancer research·2000
Same author

Rapid detection of the factor V Leiden (1691 G > A) and haemochromatosis (845 G > A) mutation by fluorescence resonance energy transfer (FRET) and real time PCR.

Journal of clinical pathology·2000
Same author

Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: is the disease multifocal?

British journal of haematology·1998
Same author

A method for assessing strand breaks in DNA.

Analytical biochemistry·1998

Related Experiment Video

Updated: Jun 4, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Quantifying residual leukemia by "clone-specific" polymerase chain reaction.

M J Brisco1

  • 1Department of Haematology, Flinders University of South Australia and Flinders Medical Center, Bedford Park, South Australia.

Methods in Molecular Medicine
|February 12, 2011
PubMed
Summary

This study identifies the rearranged immunoglobulin heavy-chain (IgH) gene as a reliable marker for detecting minimal residual disease in B-lineage acute lymphoblastic leukemia (ALL). A sensitive polymerase chain reaction (PCR) test can quantify cancer cells in 60-70% of ALL patients.

More Related Videos

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

  • Molecular biology
  • Oncology
  • Immunology

Background:

  • Molecular biology tests offer sensitive cancer cell quantification when genetic markers are known.
  • Acute lymphoblastic leukemia (ALL) presents numerous genetic abnormalities, but few are suitable for sensitive quantification.
  • Identifying reliable markers for minimal residual disease (MRD) in ALL is crucial for treatment monitoring.

Purpose of the Study:

  • To establish a sensitive and quantitative method for detecting minimal residual disease (MRD) in B-lineage acute lymphoblastic leukemia (ALL).
  • To utilize the rearranged immunoglobulin heavy-chain (IgH) gene as a specific clonal marker for MRD quantification in ALL.

Main Methods:

  • Development of a highly sensitive, quantitative polymerase chain reaction (PCR) test.
  • Design of "clone-specific" primers targeting the rearranged immunoglobulin heavy-chain (IgH) gene.
  • Application of the PCR test to identify and quantify residual leukemia clones.

Main Results:

  • The rearranged immunoglobulin heavy-chain (IgH) gene serves as an effective clonal marker for B-lineage ALL.
  • A quantitative PCR test using clone-specific primers can be developed for 60-70% of B-lineage ALL cases.
  • This method allows for the sensitive quantification of extremely low levels of cancer cells.

Conclusions:

  • The rearranged immunoglobulin heavy-chain (IgH) gene is a viable and sensitive marker for MRD detection in a majority of B-lineage ALL cases.
  • Quantitative PCR targeting the IgH gene provides a powerful tool for monitoring treatment response and relapse in ALL patients.
  • This approach enhances the ability to quantify residual disease, improving patient management strategies.